“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

Radionuclide drug conjugates (RDCs) have emerged as transformative agents that integrate diagnosis and therapy into a single ...

Vaxcyte aims to revolutionize the pneumococcal vaccine market with VAX-31. Click here to read an analysis of PCVX stock now.

The country has reduced the number of children who had never been vaccinated by half, according to The Lancet.

In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...

The U.S. childhood immunization schedule, the grid of colored bars pediatricians share with parents, recommends a set of vaccines given from birth through adolescence to prevent a range of serious ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

Astellas Pharma announces positive topline results from phase 3 EV-304 clinical trial of Padcev plus Keytruda: Tokyo Friday, December 19, 2025, 10:00 Hrs [IST] Astellas Pharma Inc ...

Immunome (IMNM) surges after positive phase 3 results for varegacestat in desmoid tumors. Read the latest analysis on the ...

Merck and Daiichi Sankyo acknowledged a "voluntary pause" in the phase III program for the investigational antibody-drug conjugate ifinatamab deruxtecan following a higher-than-expected number of ...

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...